ZA981206B - Use of NMDA receptor antagonist - Google Patents

Use of NMDA receptor antagonist

Info

Publication number
ZA981206B
ZA981206B ZA981206A ZA981206A ZA981206B ZA 981206 B ZA981206 B ZA 981206B ZA 981206 A ZA981206 A ZA 981206A ZA 981206 A ZA981206 A ZA 981206A ZA 981206 B ZA981206 B ZA 981206B
Authority
ZA
South Africa
Prior art keywords
receptor antagonist
nmda receptor
nmda
antagonist
receptor
Prior art date
Application number
ZA981206A
Inventor
Timothy Michael Skerry
Larry John Suva
Original Assignee
Smith & Nephew
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smith & Nephew filed Critical Smith & Nephew
Publication of ZA981206B publication Critical patent/ZA981206B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
ZA981206A 1997-02-14 1998-02-13 Use of NMDA receptor antagonist ZA981206B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9703109.0A GB9703109D0 (en) 1997-02-14 1997-02-14 Compositions

Publications (1)

Publication Number Publication Date
ZA981206B true ZA981206B (en) 1999-03-26

Family

ID=10807681

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA981206A ZA981206B (en) 1997-02-14 1998-02-13 Use of NMDA receptor antagonist

Country Status (7)

Country Link
EP (1) EP0971712A1 (en)
JP (1) JP2001513757A (en)
AU (1) AU6001798A (en)
CA (1) CA2280722A1 (en)
GB (1) GB9703109D0 (en)
WO (1) WO1998035674A1 (en)
ZA (1) ZA981206B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1221963A4 (en) * 1999-07-28 2006-03-22 Univ Pennsylvania Methods of inhibiting osteoclastogenesis
WO2002050302A2 (en) * 2000-12-21 2002-06-27 Myriad Genetics, Inc. Protein-protein interactions
US20080194698A1 (en) * 2005-03-07 2008-08-14 Michael Hermanussen Nmda Receptor Antagonists in the Medical Intervention of Metabolic Disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0586521A1 (en) * 1991-05-28 1994-03-16 The Procter & Gamble Company Calcium, trace mineral, vitamin d and drug therapy combinations
GB9125515D0 (en) * 1991-11-29 1992-01-29 Merck Sharp & Dohme Therapeutic agents
FR2711992A1 (en) * 1993-11-03 1995-05-12 Lipha New heterocyclic derivatives, process of preparation and pharmaceutical composition containing them
CZ217697A3 (en) * 1995-01-10 1998-03-18 Smithkline Beecham S. P. A. Indole derivatives, which can be used for treating osteoporosis, process of their preparation, pharmaceutical composition containing such derivatives and use
UA51676C2 (en) * 1995-11-02 2002-12-16 Пфайзер Інк. (-)cis-6(S)-phenyl-5(R)-[4-(2-pyrrolidin-I-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol D-tartrate, a method of its preparation, method of THE treatment OF diseases medicated by agonists of estrogen and a pharmaceutical composition

Also Published As

Publication number Publication date
WO1998035674A1 (en) 1998-08-20
CA2280722A1 (en) 1998-08-20
JP2001513757A (en) 2001-09-04
GB9703109D0 (en) 1997-04-02
AU6001798A (en) 1998-09-08
EP0971712A1 (en) 2000-01-19

Similar Documents

Publication Publication Date Title
HK1029574A1 (en) 1-amino-alkylcyclohexane nmda receptor antagonists
EP1000031A4 (en) Vitronectin receptor antagonist
HU9603525D0 (en) Vironectin receptor antagonists
HU9601529D0 (en) Pyrimidinedion-, pyrimidinetrion-, triazinedion-, tetrahydro-quinazolinedion- derivatives as alpha-adrenerg receptor antagonists
HU9801887D0 (en) Ccr-3 receptor antagonists
ZA98691B (en) Use of central cannabinoid receptor antagonists for the preparation of drugs
HUP9900754A3 (en) Vitronectin receptor antagonists
EP0895475A4 (en) Vitronectin receptor antagonists
ZA9896B (en) Vitronectin receptor antagonists
ZA9610736B (en) 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists
ZA951345B (en) Adhesion receptor antagonist
PL341114A1 (en) Antagonists of thrombosin receptors
IL135189A0 (en) Vitronectin receptor antagonist
IL135188A0 (en) Vitronectin receptor antagonist
PL339381A1 (en) Antagonists of vitronectin receptor
AU3234395A (en) Glycine receptor antagonist pharmacophore
PL330195A1 (en) Antagonist of dopamine d4 receptor
PL335100A1 (en) Oxazolynones as antagonists of 5ht2a receptor
EG24025A (en) Vitronectin receptor antagonist
PL320638A1 (en) Antagonists of endothein receptors
ZA981206B (en) Use of NMDA receptor antagonist
AU6826498A (en) Endotholin receptor antagonists
ZA968939B (en) Fibrinogen receptor antagonist
ZA986620B (en) Fibrinogen receptor antagonist
ZA988562B (en) Vitronectin receptor antagonists